Briefing
Attitudes of cancer patients toward ctDNA-based liquid biopsy for follow-up
This single-center Belgian survey (Antwerp University Hospital) assessed attitudes toward ctDNA liquid biopsy among 195 patients in cancer treatment or follow-up. Only 10% had heard of circulating tumor DNA. In hypothetical scenarios that assumed proven clinical validity, 79% accepted its use to guide adjuvant treatment, and 85% expected better quality of life with home- or general-practitioner blood draws.
- Design: Evidence level 3
- Assay: Not named in the abstract
Molecular OncologyPubMed 42905048DOI 10.1002/1878-0261.70352